Monte Rosa Therapeutics, Inc. Other Comprehensive (Income) Loss, Defined Benefit Plan, before Tax, after Reclassification Adjustment, Attributable to Parent
Monte Rosa Therapeutics, Inc. (GLUE) reported Other Comprehensive (Income) Loss, Defined Benefit Plan, before Tax, after Reclassification Adjustment, Attributable to Parent of -$1.59 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent · last filed 2026-03-17
- Monte Rosa Therapeutics, Inc. other comprehensive (income) loss, defined benefit plan, before tax, after reclassification adjustment, attributable to parent for fiscal 2025 was -$1.59M, a 2086.25% decline from fiscal 2024.
- Monte Rosa Therapeutics, Inc. other comprehensive (income) loss, defined benefit plan, before tax, after reclassification adjustment, attributable to parent for fiscal 2024 was $80.00K.
- Monte Rosa Therapeutics, Inc. other comprehensive (income) loss, defined benefit plan, before tax, after reclassification adjustment, attributable to parent for fiscal 2023 was -$1.24M.
- Monte Rosa Therapeutics, Inc. other comprehensive (income) loss, defined benefit plan, before tax, after reclassification adjustment, attributable to parent for fiscal 2022 was $0.00.
| Period end | Other Comprehensive (Income) Loss, Defined Benefit Plan, before Tax, after Reclassification Adjustment, Attributable to Parent 12 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, before Tax, after Reclassification Adjustment, Attributable to Parent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$1.59M 10-K · filed 2026-03-17 | |
| 2024-12-31 | $80.00K 10-K · filed 2026-03-17 | -$1.04M 10-K · filed 2025-03-20 |
| 2023-12-31 | -$1.24M 10-K · filed 2025-03-20 | |
| 2022-12-31 | $0.00 10-K · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |